SPTLC3
Serine palmitoyltransferase 3
Also known as: C20orf38, FLJ11112, hLCB2b, LCB2B, SPTC3_HUMAN, SPTLC2L
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9NUV7
- Gene
- SPTLC3
- Ensembl
- ENSG00000172296
- Chromosome
- 20
- Canonical length
- 552 aa
- Protein class
- Enzymes, Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Microtubules
OverviewNCBI Gene
This gene encodes a subunit of the serine palmitoyltransferase complex which catalyzes the rate-limiting step in sphingolipid biosynthesis. This subunit metabolizes lauroyl- and myristoyl-CoA and generates C14 and C16-sphingoid bases. [provided by RefSeq, Mar 2017]
Canonical amino-acid sequenceUniProt
552 residues, UniProt reviewed canonical sequence.
>Q9NUV7|SPTLC3
1 MANPGGGAVC NGKLHNHKKQ SNGSQSRNCT KNGIVKEAQQ NGKPHFYDKL IVESFEEAPL
61 HVMVFTYMGY GIGTLFGYLR DFLRNWGIEK CNAAVERKEQ KDFVPLYQDF ENFYTRNLYM
121 RIRDNWNRPI CSAPGPLFDL MERVSDDYNW TFRFTGRVIK DVINMGSYNF LGLAAKYDES
181 MRTIKDVLEV YGTGVASTRH EMGTLDKHKE LEDLVAKFLN VEAAMVFGMG FATNSMNIPA
241 LVGKGCLILS DELNHTSLVL GARLSGATIR IFKHNNTQSL EKLLRDAVIY GQPRTRRAWK
301 KILILVEGVY SMEGSIVHLP QIIALKKKYK AYLYIDEAHS IGAVGPTGRG VTEFFGLDPH
361 EVDVLMGTFT KSFGASGGYI AGRKDLVDYL RVHSHSAVYA SSMSPPIAEQ IIRSLKLIMG
421 LDGTTQGLQR VQQLAKNTRY FRQRLQEMGF IIYGNENASV VPLLLYMPGK VAAFARHMLE
481 KKIGVVVVGF PATPLAEARA RFCVSAAHTR EMLDTVLEAL DEMGDLLQLK YSRHKKSARP
541 ELYDETSFEL EDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SPTLC3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.3
- Highest tissue expression
- 24 nTPM
Expression across tissuesHPA
Tissue
- skin: 24 nTPM
- thyroid gland: 23 nTPM
- placenta: 20 nTPM
- liver: 19 nTPM
- kidney: 17 nTPM
- epididymis: 16 nTPM
Single-cell type
- endometrial glandular cells: 284 nCPM
- pituicytes/fscs: 183 nCPM
- renal collecting duct intercalated cells: 180 nCPM
- sertoli cells: 154 nCPM
- salivary ionocytes: 134 nCPM
- proximal tubule cells: 128 nCPM
Immune cell
- NK-cell: 1.5 nTPM
- MAIT T-cell: 0.9 nTPM
- naive CD4 T-cell: 0.2 nTPM
- gdT-cell: 0.1 nTPM
- memory CD4 T-cell: 0.1 nTPM
- basophil: 0 nTPM
Brain region
- choroid plexus: 18 nTPM
- thalamus: 8.9 nTPM
- hypothalamus: 6.7 nTPM
- medulla oblongata: 6.1 nTPM
- white matter: 6.1 nTPM
- pons: 5.7 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about SPTLC3.
Disease | GeneticClinVar
1 pathogenic / likely-pathogenic of 81 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Peripheral neuropathy
- Sensory neuropathy
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.83
- gnomAD pLI
- 0
- gnomAD missense Z
- 1.17
- DepMap mean gene effect
- 0.04
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- ceramide biosynthetic process
- sphingolipid biosynthetic process
- sphingosine biosynthetic process
- sphingoid biosynthetic process
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Aminotransferase, class-II, pyridoxal-phosphate binding site
- Aminotransferase, class I/classII, large domain
- Pyridoxal phosphate-dependent transferase, major domain
- Pyridoxal phosphate-dependent transferase, small domain
- Pyridoxal phosphate-dependent transferase
- 8-amino-7-oxononanoate synthase class-II
- Aminotransferase class I and II
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SPTLC3 as an antibody target. Whether an autoantibody or antibody against SPTLC3 could matter depends on whether native SPTLC3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SPTLC3 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label SPTLC3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...